Prestige Consumer Healthcare (NYSE:PBH) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a report released on Tuesday morning.

A number of other analysts have also recently issued reports on the stock. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research note on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. DA Davidson restated a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Trading Up 0.9 %

Shares of NYSE:PBH opened at $74.45 on Tuesday. Prestige Consumer Healthcare has a 52-week low of $58.22 and a 52-week high of $86.36. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The company has a market capitalization of $3.68 billion, a P/E ratio of 18.11, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51. The company has a 50-day simple moving average of $80.56 and a 200 day simple moving average of $74.17.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business’s revenue was down .9% on a year-over-year basis. During the same period last year, the firm posted $1.07 earnings per share. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock valued at $3,187,300 over the last quarter. 1.60% of the stock is owned by company insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds have recently added to or reduced their stakes in PBH. Nordea Investment Management AB lifted its stake in shares of Prestige Consumer Healthcare by 3.4% in the 4th quarter. Nordea Investment Management AB now owns 90,693 shares of the company’s stock valued at $7,066,000 after acquiring an additional 2,985 shares during the last quarter. GAMMA Investing LLC raised its position in Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock valued at $108,000 after purchasing an additional 220 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after purchasing an additional 8,533 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Prestige Consumer Healthcare by 4.3% during the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after purchasing an additional 894 shares during the last quarter. Finally, Sanctuary Advisors LLC increased its stake in shares of Prestige Consumer Healthcare by 11.0% in the third quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock valued at $1,244,000 after buying an additional 1,715 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.